Preparation and characterization of a chimeric CD19 monoclonal antibody - PubMed (original) (raw)

. 1991 Dec:69 ( Pt 6):411-22.

doi: 10.1038/icb.1991.58.

Affiliations

• PMID: 1725979
• DOI: 10.1038/icb.1991.58

Preparation and characterization of a chimeric CD19 monoclonal antibody

H Zola et al. Immunol Cell Biol. 1991 Dec.

Abstract

FMC63 is an IgG2a mouse monoclonal antibody belonging to the CD19 cluster. CD19 antibodies react with a 95kDa protein expressed by cells of the B lymphocyte lineage, from pre-B cells to mature B lymphocytes. CD19 antibodies have been suggested as candidates for immunological attack on leukaemic and lymphoma cells of the B lineage because the antigen is restricted to the B lineage. With the potential use of FMC63 in immunotherapy in mind, we have produced a mouse-human chimera in which the genes coding for the VDJ region of the heavy chain and the VJ region of the light chain derive from the FMC63 mouse hybridoma, while the C region genes code for human IgG1. The genes have been transfected back into a mouse myeloma line, which secretes low levels of immunoglobulin. (Ig). This Ig was purified and biotinylated in order to determine the specificity of the antibody. The chimeric antibody has a reaction profile concordant with the original FMC63 antibody, but has the properties of a human IgG1, including the ability to fix human complement. However, the antibody is not cytotoxic in vitro in the presence of complement or cells capable of mediating antibody-dependent cellular cytotoxicity. Possible reasons for this and ways of using the antibody are discussed.

PubMed Disclaimer

Similar articles

• Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
  Hooijberg E, van den Berk PC, Sein JJ, Wijdenes J, Hart AA, de Boer RW, Melief CJ, Hekman A. Hooijberg E, et al. Cancer Res. 1995 Feb 15;55(4):840-6. Cancer Res. 1995. PMID: 7531616
• In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.
  Pietersz GA, Wenjun L, Sutton VR, Burgess J, McKenzie IF, Zola H, Trapani JA. Pietersz GA, et al. Cancer Immunol Immunother. 1995 Jul;41(1):53-60. doi: 10.1007/BF01788960. Cancer Immunol Immunother. 1995. PMID: 7543822 Free PMC article.
• Characterization of a human T cell-specific chimeric antibody (CD7) with human constant and mouse variable regions.
  Heinrich G, Gram H, Kocher HP, Schreier MH, Ryffel B, Akbar A, Amlot PL, Janossy G. Heinrich G, et al. J Immunol. 1989 Dec 1;143(11):3589-97. J Immunol. 1989. PMID: 2479683
• Fidelity and infidelity in commitment to B-lymphocyte lineage development.
  Rolink AG, Schaniel C, Busslinger M, Nutt SL, Melchers F. Rolink AG, et al. Immunol Rev. 2000 Jun;175:104-11. Immunol Rev. 2000. PMID: 10933595 Review.
• Single B cell antibody technologies.
  Tiller T. Tiller T. N Biotechnol. 2011 Sep;28(5):453-7. doi: 10.1016/j.nbt.2011.03.014. Epub 2011 Apr 5. N Biotechnol. 2011. PMID: 21473940 Free PMC article. Review.

Cited by

• Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy.
  Camus V, Houot R, Brisou G, Tessoulin B, Bailly S, Sesques P, Decroocq J, Krzisch D, Oberic L, Lemonnier F, Bouabdallah K, Campidelli A, Tounes L, Abraham J, Herbaux C, Morschhauser F, Damaj GL, Guidez S, Carras S, Fornecker LM, Choquet S, Hermine O, Paillassa J, Chauchet A, Casasnovas O, Drieu La Rochelle L, Castilla-Llorente C, Joris M, Dupont V, Marquet A, Le Gouill S, Jardin F. Camus V, et al. Blood Adv. 2024 Oct 22;8(20):5371-5381. doi: 10.1182/bloodadvances.2024013726. Blood Adv. 2024. PMID: 39163620 Free PMC article.
• Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia.
  Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S, Binder M. Märkl F, et al. Nat Commun. 2024 Feb 2;15(1):993. doi: 10.1038/s41467-024-45378-w. Nat Commun. 2024. PMID: 38307904 Free PMC article.
• _De novo_-designed minibinders expand the synthetic biology sensing repertoire.
  Weinberg ZY, Soliman SS, Kim MS, Shah DH, Chen IP, Ott M, Lim WA, El-Samad H. Weinberg ZY, et al. bioRxiv [Preprint]. 2024 Aug 29:2024.01.12.575267. doi: 10.1101/2024.01.12.575267. bioRxiv. 2024. PMID: 38293112 Free PMC article. Preprint.
• Solving the mystery of the FMC63-CD19 affinity.
  Seigner J, Zajc CU, Dötsch S, Eigner C, Laurent E, Busch DH, Lehner M, Traxlmayr MW. Seigner J, et al. Sci Rep. 2023 Dec 27;13(1):23024. doi: 10.1038/s41598-023-48528-0. Sci Rep. 2023. PMID: 38155191 Free PMC article.
• Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting.
  Ruffo E, Butchy AA, Tivon Y, So V, Kvorjak M, Parikh A, Adams EL, Miskov-Zivanov N, Finn OJ, Deiters A, Lohmueller J. Ruffo E, et al. Nat Commun. 2023 May 9;14(1):2463. doi: 10.1038/s41467-023-37863-5. Nat Commun. 2023. PMID: 37160880 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • Cellosaurus - a cell line knowledge resource